Search Results 1081-1090 of 17095 for monoclonal antibody

1. Rheumatology - Clinical trials

   ... antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. A Study to Evaluate Cardiopulmonary Complications in ...

2. Autoimmune epilepsy - Diagnosis and treatment - Mayo Clinic

   Lab tests. Lab tests check for antibodies in the immune system that are attacking brain cells and causing seizures.

3. A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

   Prior use of lenalidomide, or monoclonal antibodies against CTLA-4, PD-1, or PD-L1. High risk of developing thromboembolic events, who are unwilling to take ...

4. Doctors and departments - Mayo Clinic

   Mayo Clinic researchers discovered an autoantibody, later called aquaporin-4-immunoglobulin G, that is a specific marker for NMO . Testing for this autoantibody ...

5. A Study to Evaluate Posoleucel ALVR105 to Treat Kidney Transplant Recipients with BK Viremia - Mayo Clinic

   ... monoclonal antibodies < 28 days prior to randomization. Receipt of other investigational antiviral treatments (e.g., anti-BK monoclonal antibodies) within ...

6. A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

   Participation eligibility · Subjects with any history of hypersensitivity to any monoclonal antibody (including mepolizumab). · Subjects with current malignancy ...

7. Loncastuximab Tesirine in WM - Clinical Trials

   the Second International Workshop on Waldenström macroglobulinemia. - At least 2 prior lines of treatment, including an anti-CD20 monoclonal antibody-containing ...

8. Diseases and Conditions that Start with M - Mayo Clinic

   Monoclonal gammopathy of undetermined significance (MGUS) ... MOG antibody-associated disorder. See. Myelin ... Monoclonal gammopathy of undetermined significance ( ...

9. A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies - Mayo Clinic

   Treatment with biological agents (including monoclonal antibodies and ... History of ≥ Grade 3 infusion-related reaction associated with antibody administration, ...

10. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma - Mayo Clinic

    Monoclonal antibody (ies). At least 28 days since the last dose of monoclonal antibody prior to first dose of tazemetostat. Immunotherapy (e.g., tumor vaccine).